PotterBanker
6 years ago
BELGRAVIA Intends to Replace the Board of Tartisan Nickel for Failure to Perform
https://globenewswire.com/news-release/2018/08/07/1547927/0/en/BELGRAVIA-Intends-to-Replace-the-Board-of-Tartisan-Nickel-for-Failure-to-Perform.html
TORONTO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE: BLGV) (OTCQB: BLGVF) (“Belgravia”) today issued an open letter to the shareholders of Tartisan Nickel Corporation (“Tartisan” or the “Company”) (CSE: TN) notifying them that Belgravia will be attempting to replace the entire board of directors (the “Board”) at the annual general and special meeting of shareholders scheduled for September 17, 2018 for the Board’s abject failure to create shareholder value. The text of Belgravia’s open letter is below:
Dear Fellow Shareholders,
Belgravia first invested in Tartisan in March 2018 and to date has invested over $800,000. The return that the Tartisan Board gave us on our investment has wiped out approximately half our initial share value. We know that other shareholders have suffered far worse losses as a result of the current Board’s incompetence.
PotterBanker
6 years ago
Belgravia Dermatology Completes Identification of Initial Drug Targets Within the Skin Endocannabinoid System and Also Identifies Bio Markers for Pre Clinical Work in Acne
https://globenewswire.com/news-release/2018/06/18/1525693/0/en/Belgravia-Dermatology-Completes-Identification-of-Initial-Drug-Targets-Within-the-Skin-Endocannabinoid-System-and-Also-Identifies-Bio-Markers-for-Pre-Clinical-Work-in-Acne.html
TORONTO, June 18, 2018 (GLOBE NEWSWIRE) -- BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) (“Belgravia” or the “Company”) today announced that its subsidiary, Belgravia Dermatology Inc. (“Belgravia Dermatology”) has completed the selection of initial drug targets and biological markers for its pre-clinical work in cannabinoid based dermatological treatments for unmet medical needs. The Company’s indications of interest include acne, atopic dermatitis, and psoriasis. The initial focus of product development is acne.
PotterBanker
7 years ago
BELGRAVIA CAPITAL completes acquisition of interest in R&D Pharma Corp., a Canadian corporation building a vertically integrated medical cannabis business in Jamaica
https://globenewswire.com/news-release/2018/05/30/1513731/0/en/BELGRAVIA-CAPITAL-completes-acquisition-of-interest-in-R-D-Pharma-Corp-a-Canadian-corporation-building-a-vertically-integrated-medical-cannabis-business-in-Jamaica.html
TORONTO, May 30, 2018 (GLOBE NEWSWIRE) -- BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) (“Belgravia Capital”, “Belgravia”, or the “Company”) is pleased to announce that it has acquired 10.03% of the outstanding common shares of R&D Pharma Corp. (“RDP”). RDP is a Canadian corporation developing a vertically integrated medicinal cannabis business in Jamaica. Belgravia has acquired four million (4 million) common shares of RDP at a price of twenty-five (25) cents per share. Belgravia has the right to appoint an independent director to the Board of RDP. Mr. Kevin Strong, the Chief Financial Officer (“CFO”) of Belgravia, has been appointed CFO of RDP. The funding of the acquisition was by way of Canadian $500,000 (five-hundred thousand dollars) and 5,000,000 (five million) common shares of Belgravia.
PotterBanker
7 years ago
Belgravia Completes Transition of ICP Organics to Dermatology Product Development, Renames ICP Organics to Belgravia Dermatology Inc., and Appoints Sidney Himmel Director of Belgravia Dermatology
TORONTO, May 11, 2018 (GLOBE NEWSWIRE) -- BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) (“Belgravia” or the “Company”) today announced that it has completed the strategic transition of ICP Organics, the fully owned subsidiary of Belgravia, to a cannabinoid-based dermatology ethical drug research and product development company. Further, the name of ICP Organics, the dermatology division of Belgravia, is being changed to Belgravia Dermatology Inc. (“Belgravia Dermatology”). The Company has also announced today that Sidney Himmel has been appointed as director of Belgravia Dermatology.
https://globenewswire.com/news-release/2018/05/11/1500957/0/en/Belgravia-Completes-Transition-of-ICP-Organics-to-Dermatology-Product-Development-Renames-ICP-Organics-to-Belgravia-Dermatology-Inc-and-Appoints-Sidney-Himmel-Director-of-Belgravia.html
PotterBanker
7 years ago
If the LOI with FanLogic isn't sexy
I suppose closing the LOI may not be sexy either, except that it could have revenue projections or blockchain platform details that are exciting.
The blockchain thing is for real and will be the way that most transactions and other data like a rewards program, or seed to sales records, or other ledgers get done. It's just a matter of time.
Whether that does anything for Belgravia or not remains to be seen.TORONTO , Jan. 25, 2018 (GLOBE NEWSWIRE) -- BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE:BLGV) (OTCQB:BLGVF) (“Belgravia Capital”, “Belgravia”, or the “Company”) is pleased to announce the execution of a letter of intent with Fanlogic Interactive Inc. (“Fanlogic”) for the joint development of the world’s first unified cannabis automated industry loyalty rewards program. The program will be developed on a Belgravia/Fanlogic Blockchain proprietary platform. The revenue model will include set up fees, and the generation of commissions on smart-contracted incremental and tracked customer purchases.
The program will be customer accessible on mobile and other electronic media distributed apps. The blockchain-distributed app will provide real-time loyalty reward points to customers of licensed distributors and other legal distributors of medicinal cannabis and related products.
https://globenewswire.com/news-release/2018/01/25/1304824/0/en/BELGRAVIA-CAPITAL-INTERNATIONAL-and-Fanlogic-Commence-Design-of-Blockchain-Loyalty-Program-for-the-Global-Cannabis-Industry.html